The FDA approved a new use for a drug to reduce the risk of cardiovascular disease, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight.

Popular brands of the GLP-1 receptor agonist semaglutide — including Ozempic and Rybelsus —are approved by the Food and Drug Administration (FDA) for treating diabetes, while …

Oct 2, 2024 · FDA is aware that some patients and health care professionals may look to unapproved versions of GLP-1 (glucagon-like peptide-1 (GLP-1) receptor agonists) drugs, …

May 20, 2024 · Weight regain is common after discontinuing GLP-1 medications. Due to promising research, Wegovy was recently approved by the Food and Drug Administration …

Nov 4, 2024 · For T2D, semaglutide is FDA-approved as Ozempic, liraglutide as Victoza, and tirzepatide as Mounjaro. These formulations have been used off-label for weight loss but are …

Nov 14, 2023 · The FDA recently approved a new Eli Lilly drug, Zepbound (tirzepatide), for chronic weight management in adults with at least one weight-related health condition.

Jan 8, 2025 · Retatrutide generated weight loss of more than 22% after 48 weeks. Each of those drugs are taken once a week, by an injection. By comparison, the FDA-approved drug …

Nov 1, 2023 · Two of these GLP-1 receptor agonists are FDA-approved in formulations specifically designed for weight loss in people without diabetes: liraglutide (Saxenda) and …

Jan 1, 2025 · The FDA has approved three GLP-1 receptor agonist drugs for weight loss. The drugs not only lower blood sugar and weight, but also reduce the risks for many health …

Zepbound activates receptors of hormones secreted from the intestine (glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)) to reduce appetite and food …